Patent application number | Description | Published |
20080274996 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 11-06-2008 |
20110009472 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 01-13-2011 |
20120202873 | RNAi Probes Targeting Cancer-Related Proteins - RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. | 08-09-2012 |
Patent application number | Description | Published |
20090263326 | NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. | 10-22-2009 |
20100202974 | NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. | 08-12-2010 |
20130189187 | NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. | 07-25-2013 |
Patent application number | Description | Published |
20080222659 | ABSTRACTING OPERATING ENVIRONMENT FROM OPERATING SYSTEM - The present invention extends to methods, systems, and computer program products for abstracting an operating environment from an operating system running in the operating environment. Within an operating environment, an operating environment abstraction layer abstracts and exposes operating environment resources to an operating system. Accordingly, appropriately configured operating environment abstraction layers provide the operating system with a uniform interface to available resources across a variety of different operating environments. Each operating environment abstraction layer and the operating system include adjustable algorithms that can be adjusted to appropriately provide services to requesting applications based on exposed resources of the operating environment. Abstraction layers can be configured to analyze and become fully aware of their operating environment, including identifying the presence of other abstraction layers. An operating system and corresponding abstraction layer can be run in flexible combinations of privileged and unprivileged processor modes. | 09-11-2008 |
20090100435 | HIERARCHICAL RESERVATION RESOURCE SCHEDULING INFRASTRUCTURE - Scheduling system resources. A system resource scheduling policy for scheduling operations within a workload is accessed. The policy is specified on a workload basis such that the policy is specific to the workload. System resources are reserved for the workload as specified by the policy. Reservations may be hierarchical in nature where workloads are also hierarchically arranged. Further, dispatching mechanisms for dispatching workloads to system resources may be implemented independent from policies. Feedback regarding system resource use may be used to determine policy selection for controlling dispatch mechanisms. | 04-16-2009 |
20090328058 | PROTECTED MODE SCHEDULING OF OPERATIONS - The present invention extends to methods, systems, and computer program products for protected mode scheduling of operations. Protected mode (e.g., user mode) scheduling can facilitate the development of programming frameworks that better reflect the requirements of the workloads through the use of workload-specific execution abstractions. In addition, the ability to define scheduling policies tuned to the characteristics of the hardware resources available and the workload requirements has the potential of better system scaling characteristics. Further, protected mode scheduling decentralizes the scheduling responsibility by moving significant portions of scheduling functionality from supervisor mode (e.g., kernel mode) to an application. | 12-31-2009 |
20120165977 | Robotic Drive System Modularity - The subject disclosure is directed towards a robot device including a computational intelligence system that can be coupled to/decoupled from different interchangeable mobility mechanisms at different times. The robot may operate with its intelligence portion detached from the mobility portion, whereby the intelligence portion may be easily to interact therewith out lifting the (typically dirty) mobility mechanism. The robot may operate according to a coupled state, a decoupled state, or in a transition state when being moved for purposes of coupling or decoupling. | 06-28-2012 |
20120313779 | NOMADIC SECURITY DEVICE WITH PATROL ALERTS - There is provided a device such as a robot that includes a processor and a number of sensors. Each of the sensors provides respective sensor data to the processor. The sensor data from each sensor is indicative of corresponding characteristics of an environment of the device. A memory includes a security mode component that is executable by the processor and is configured to cause the device to autonomously navigate at least a portion of the environment. A detection component executable by the processor is configured to detect an unusual condition in the environment. | 12-13-2012 |
20120316676 | INTERACTIVE ROBOT INITIALIZATION - Initial interaction between a mobile robot and at least one user is described herein. The mobile robot captures several images of its surroundings, and identifies existence of a user in at least one of the several images. The robot then orients itself to face the user, and outputs an instruction to the user with regard to the orientation of the user with respect to the mobile robot. The mobile robot captures images of the face of the user responsive to detecting that the user has followed the instruction. Information captured by the robot is uploaded to a cloud-storage system, where information is included in a profile of the user and is shareable with others. | 12-13-2012 |
20120316679 | PROVIDING REMOTE GESTURAL AND VOICE INPUT TO A MOBILE ROBOT - A system, such as a robot, which responds to voice, gesture and other natural inputs from a user, is controllable when the user is out of range through use of a wireless controller. The wireless controller provides inputs that allow the user to enter commands that are a proxy for the voice and gesture inputs the robot otherwise recognizes. The controller can include, for example, a microphone for voice input, a pad for directional control, and a speaker and display devices to provide responses from the robot. | 12-13-2012 |
20120320033 | MOBILE PLATFORM FOR AUGMENTED REALITY - A mobile image processing manager may include an image data receiving engine configured to obtain a first set of three-dimensional (3-D) image data associated with an observation environment. The mobile image processing manager may also include a navigational plan engine configured to determine a navigational plan based on the first set. A navigation manager may be configured to initiate a navigation event based on the navigational plan. A scene determination engine may be configured to determine a first group of one or more graphical images. An image projection engine may be configured to initiate a display of the first group on a first surface, the display based on a light source. | 12-20-2012 |
20120320343 | ILLUMINATED SKIN ROBOT DISPLAY - There is provided a robot that includes a processor executing instructions that determine a desired image to be displayed. The processor issues control signals corresponding to the desired image to be displayed. The robot also comprises a display assembly including a visual projector, a mirror, and a display surface. The visual projector and mirror are disposed within the robot. The visual projector projects light corresponding to the desired image onto the mirror. The mirror receives the light from the projector, and reflects the light onto the display surface. The display surface receives the light. The image is visible on the display surface from outside the robot. | 12-20-2012 |
Patent application number | Description | Published |
20100209940 | FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: | 08-19-2010 |
20120045781 | PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described. | 02-23-2012 |
20140295469 | In Vitro Assessment of Cardiovascular Events by Assay for Neo-Eptitopes of Titin Protein - A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding. Partial sequences of titin that may be detected include: | 10-02-2014 |